The piece covers the launch of bit.bio's Custom ioDisease Model Cells at the SynBioBeta conference.
The piece covers the launch of bit.bio's Custom ioDisease Model Cells at the SynBioBeta conference.
The piece covers the launch of bit.bio's Custom ioDisease Model Cells at the SynBioBeta conference.
The piece covers the launch of bit.bio's Custom ioDisease Model Cells at the SynBioBeta conference.
Mark Kotter shares his thoughts in Labiotech on the importance of government support in enabling the UK to become a leading scienc...
Mark Kotter, CEO shares his thoughts on Synbio and how the UK can support and expand this sector and become a powerhouse of scienc...
Our CEO gives his take on what's in store for the biotech industry in 2023 as part of this forward looking feature.
This series explores the fascinating interface between science and design. Episode 2 looks at synthetic biology and features our ...
In this Financial Times piece our CEO is reflecting on raising concerns about the lab spaces for rent within science clusters.
This piece covers how bit.bio's technology is also used by Meatable for their cultured meat products.
Dr Farah Patell-Socha and Furqan Iqbal interviewed in the latest issue of Technology Networks.
VP of Research Products Dr Farah Patell-Socha discusses more accurate cell models in neurodegeneration.